Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5789)
All Articles published online
|
Publishing Process of This Article
|
Sep 21, 2024 (publication date) through Dec 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Caballero-Mateos AM, Cañadas-de la Fuente GA. Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management. World J Gastroenterol 2024; 30(35): 3942-3953 [PMID: 39351053 DOI: 10.3748/wjg.v30.i35.3942] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Caballero-Mateos AM, Cañadas-de la Fuente GA. Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management. World J Gastroenterol 2024; 30(35): 3942-3953 [PMID: 39351053 DOI: 10.3748/wjg.v30.i35.3942] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v30/i35/3942.htm |
| Number | Citing Articles |
| 1 |
Viviana Parra-Izquierdo, Juan Sebastián Frías-Ordoñez, Fabio Leonel Gil-Parada, William Otero-Regino, Jonathan Barreto Perez, German Manuel Tovar Fierro, Fabian Eduardo Puentes-Manosalva, Pedro Eduardo Cuervo Pico, María Teresa Galiano, Javier Riveros, Alvaro Andrés Gomez-Venegas, Carlos Andrés Medrano Almanza, Daniel Perea, Manuel Ballesteros, Carlos Augusto Cuadros Mendoza, Cristian Florez-Sarmiento. Experiencia en mundo real con el uso de upadacitinib en inducción para enfermedad inflamatoria intestinal en Colombia: uparecol-induction. Revista de Gastroenterología del Perú 2025; 45(3): 255 doi: 10.47892/rgp.2025.453.1904
|
| 2 |
Hongkun Li, Yuyue Zhang, Simin Du, Jinghan Shen, Xingyan Liu, Jie Jing. “Remodeling the intestinal immune microenvironment”: immune regulation and tissue regeneration by mesenchymal stem/stromal cells in the repair microenvironment of inflammatory bowel disease. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1543702
|
| 3 |
Aleksandar Radlović, Teodora Safiye, Elvis Mahmutović. The use of corticosteroids in the treatment of ulcerative colitis: A brief overview. Arhiv za farmaciju 2025; 75(3): 167 doi: 10.5937/arhfarm75-57020
|
| 4 |
Muhammad Umar Ahsan, Syeda Laiba Sajid, Rahul Balach, Muhammad Daniyal, Noor Ul Ain, Muhammad Mudasir. Emerging role of Janus kinase inhibitors in ulcerative colitis management. World Journal of Gastrointestinal Pharmacology and Therapeutics 2025; 16(4): 110472 doi: 10.4292/wjgpt.v16.i4.110472
|
| 5 |
Antonio M. Caballero-Mateos, Eduard Brunet-Mas, Beatriz Gros. Systemic Consequences of Inflammatory Bowel Disease Beyond Immune-Mediated Manifestations. Journal of Clinical Medicine 2025; 14(22): 7984 doi: 10.3390/jcm14227984
|
| 6 |
. Advances in Genetics 2025; doi: 10.1016/bs.adgen.2025.11.008
|
| 7 |
Antonio M. Caballero Mateos, Guillermo A. Cañadas de la Fuente, Beatriz Gros. Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies. Journal of Clinical Medicine 2025; 14(5): 1536 doi: 10.3390/jcm14051536
|
| 8 |
Md. Mizanur Rahaman, Phurpa Wangchuk, Subir Sarker, Qingdong Guan. Targeting Interferon‐Gamma (IFN‐γ)‐Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances. Mediators of Inflammation 2025; 2025(1) doi: 10.1155/mi/3181200
|
| 9 |
Duaa A. Althumairy, Rasha Abu-Khudir, Afnan I. Alandanoosi, Gehan M. Badr. Garlic Peel-Derived Phytochemicals Using GC-MS: Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Effects in Ulcerative Colitis Rat Model. Pharmaceuticals 2025; 18(7): 969 doi: 10.3390/ph18070969
|